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[I]n the not too distantfuture ... part of the newborn
screen .. . will be to look at all of the DNA and make a
solid prediction about what that child needs to watch out
for. This is a real revolution in medicine, probably unlike
anything that has happened since antibiotics were
introduced'
INTRODUCTION
State public health programs mandate newborn screening shortly after
birth for various genetic disorders that may have serious health
consequences if not identified and treated very early in life. Given the
individual and public health benefit, most of states conduct newborn
screening programs ("NBS programs") without parental consent. Recently,
two high-profile lawsuits have alerted the public of the fact that some states
are creating research biobanks, 2 storing their newborn bloodspots, and
disseminating them to outside entities for genetic research purposes that are
unrelated to the original purpose for which the bloodspots were obtained.3
Copyright 0 2011 by Sandra J. Carnahan.
* Professor of Law, South Texas College of Law; J.D., cum laude, South Texas College of Law;
LL.M. (Health Law), University of Houston.
1. Francis S. Collins, The Language of Life: DNA and the Revolution in Personalized
Medicine, YOUTUBE (Dec. 21, 2009), http://www.youtube.com/watch?v-8qxMbP2gWpU
(promoting Dr. Collins' book).
2. A biobank may be defined as "any collection of human biological material-organs,
tissue, blood, cells and other body fluids-that contains sdf at least traces of DNA or RNA that
would allow genetic analysis." Bernice S. Elger & Arthur L. Caplan, Consent and Anonymization
in Research Involving Biobanks, 7 EMBO REPORTS 661, 661 (2006); see also Mark A. Rothstein,
Expanding the Ethical Analysis of Biobanks, 33 J.L. MED. & ETHICS 89, 89 (2005) ("Biobanks are
repositories of human biological materials collected for biomedical research.").
3. See infra Part II.
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That newborn bloodspots are a valuable scientific tool, with great
potential for the public good, is not disputed. Newborn screening specimens
are valuable for medical research that can improve the health of children
and provide critical information about the roots of both child and adult
diseases.4 What is troublesome, however, is that newborn screening
programs, almost universally, do not obtain informed consent from the
newborn's parent, guardian, or managing conservator. 5 If, however, the
purpose of the blood collection is two-fold-newborn screening for disease
on the one hand, and genetic research on the other-then collecting
newborn blood samples without parental consent raises serious ethical and
legal issues.
This article begins with a brief overview of the NBS programs
common to all fifty states.6 Part II examines the claims made in lawsuits in
Texas and Minnesota.7 This article then goes beyond the issues presented in
the lawsuits, and addresses the larger concern of how to maintain the
public's trust in state newborn screening programs as medical research
progresses, and newborn bloodspots become an essential and highly
sought-after research tool.8 Part III examines whether the federal
regulations for the protection of human research subjects, and federal
guidelines for establishing research biobanks, ought to apply to state
newborn screening programs, in light of extensive and increasing federal
involvement in these programs.9 Part IV analyzes the concept of informed
consent in the context of newborn screening and research,10 and Part V
reveals the underlying fallacy of presumed consent in the genetic research
context." This article concludes that states should adopt the federal
regulations for the protection of human research subjects, and the federal
guidelines for establishing biobanks, and require, prior to the point of blood
4. SEC'ys ADVISORY COMM. ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN,
HEALTH RES. & SERVS. ADMIN., DRAFT BRIEFING PAPER: CONSIDERATIONS AND
RECOMMENDATIONS FOR NATIONAL GUIDANCE REGARDING THE RETENTION AND USE OF
RESIDUAL DRIED BLOOD SPOT SPECIMENS AFTER NEWBORN SCREENING ii (2010) [hereinafter
SEC'YS ADVISORY COMM. PAPER], available at
http://www.hrsa.gov/heritabledisorderscommittee/reports/.
5. See KATHERINE DRABIAK-SYED, IND. UNIV. CTR. FOR BIOETHICS, NEWBORN BLOOD
SPOT BANKING: APPROACHES TO CONSENT 1 (2010), available at
http://bioethics.iu.edulindex.php/download file/view/91/ ("Most states do not inform parents of
retention and research use of NBS; early screening tests can prevent avoidable injuries to
newborns. Accordingly, many state health departments do not obtain consent before storing and
using the NBS for further research.").
6. See infra Part 1.
7. See infra Part II.
8. See infra Parts Ill-V.
9. See infra Part Ill.
10. See infra Part IV.
I1. See infra Part V.
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collection, written parental consent to biobank newborn bloodspots for
future genetic research. 12 The critically important message of this article is
that if states are not forthcoming with parents regarding use of their child's
blood for genetic research, they risk a potentially disastrous result-
undermining the public's trust in essential newborn screening programs.
I. NEWBORN SCREENING PROGRAMS
Every year in the United States, nearly four million newborn babies
have their little heels pricked and squeezed to disgorge several drops of
blood that will be placed on a "Guthrie card," which consists of special
filter paper containing the bloodspot, as well as identifying information
such as the mother's name, hospital of birth, baby's medical record number,
doctor's name, and other clinical information. 13 The blood specimens are
air dried, and sent to a laboratory where the blood will be screened for a
variety of illnesses. 14 The blood specimens are accompanied with
identifying and demographic information, as well as physician or other
appropriate contact information.15 The screening, which is primarily genetic
screening, is authorized by State public health initiatives that currently exist
in all fifty states.16 Genetic screening refers to screening for "heritable
disorders that are caused by abnormalities in the individual's genes and
chromosomes." 1 7 The collective purpose of newborn screening programs is
to screen the entire population for the presence of an illness before any
12. See infra Part V.
13. For a sample Guthrie card, see Newborn Screening for Genetic Conditions, CENTRE FOR
GENETICS EDUC., http://www.genetics.com.aulfactsheet/fs20.asp (last visited May 2, 2011)
(listing information collected, including mother's name, hospital of birth, doctor's name, baby
birth weight, and date of birth, and providing a visual example of the Guthrie card).
14. See, e.g., 25 TEX. ADMIN. CODE § 37.55(c) (2011) ("Blood specimens must air-dry on a
flat surface for at least four hours and must be mailed to the department within 24 hours after
collection.").
15. See, e.g., 25 TEX. ADMIN. CODE § 37.55(d) ("Providers shall ensure that the identifying
and demographic information sheet is complete and . . . [i]dentifying information shall include
contact information for the newborn's physician or health care practitioner to ensure ability to
contact ... in case of an abnormal screen.").
16. See PRESIDENT'S COUNCIL ON BIOETHICS, THE CHANGING MORAL FOCUS OF NEWBORN
SCREENING 5-6 (2008), available at
http://bioethics.georgetown.edu/pcbe/reports/newborn screening (explaining that screening "is
almost entirely genetic screening," and that screening is conducted on the entire population).
17. See id at 6 & n.3 (noting that a few states also screen for infectious diseases such as
HIV). See generally NAT'L NEWBORN SCREENING & GENETIC RES. CTR., NATIONAL NEWBORN
SCREENING STATUS REPORT (2011), available at http://genes-r-us.uthscsa.edu/nbsdisorders.pdf
(listing the status of newborn screening in the United States by state as of January 18, 2011).
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symptoms of disease are exhibited, on the premise that early identification
of a disease might make the difference between life and death. 18
Newborn babies have been screened shortly after birth for over forty
years. In the 1960s microbiologist Robert Guthrie developed a simple,
inexpensive, test (the "Guthrie Test") for the presence of Phenylketonuria
("PKU"), a rare genetic metabolic disorder that, if left untreated, generally
results in severe mental and behavioral disabilities.1 9 Even though PKU is
quite rare, affecting only about 1 in 11,000 births, the resulting
developmental disability is preventable if the PKU newborn is placed on a
special diet; 20 once the retardation occurs, however, it cannot be reversed.
21 Thus, it became essential to test for PKU quickly. The Guthrie Test met
this need, since it could be administered shortly after birth. 22 After a
successful two year clinical trial involving over 400,000 infants, a massive
public campaign, backed by President Kennedy and the newly-created
Presidential Advisory Commission on Mental Retardation, was undertaken
to encourage states to adopt mandatory newborn screening legislation. 23
Through the years, medical knowledge and testing technology advanced
significantly, allowing laboratories to screen for many different conditions.
Today, all fifty states have mandatory NBS programs, although the number
of screened-for conditions varies among states.24 The American College of
Medical Genetics, in its effort to develop a test panel that could be adopted
uniformly by the states, recommends screening for 29 core conditions, and
another 25 conditions that could be detected when screening for the core
18. see CTR. FOR BIOETHICS, UNIV. OF MINN., NEW FRONTIERS IN GENETIC TESTING AND
SCREENING 7 (1999), available at http://www.ahc.umn.edu/img/assets/26104/Genetic Testing.pdf
(describing the purpose of genetic screening for newborns and detailing some of the diseases and
conditions that can be treated if caught early enough).
19. Diane B. Paul, The History of Newborn Phenylketonuria Screening in the U.S., in FINAL
REPORT OF THE TASK FORCE ON GENETIC SCREENING (Neil A. Holtzman & Michael S. Watson
eds., 1997), available at http://biotech.law.1su.edu/research/fed/tfgt/appendix5.htm. The Task
Force Report was created by the National Institute of Health Department of Energy Working
Group on Ethical, Legal, & Social Implications ("ELSI") of the Human Genome Research Project.
Its purpose was "to review genetic testing in the United States and make recommendations to
ensure the development of safe and effective genetic tests." Executive Summary, in FINAL REPORT
OF THE TASK FORCE ON GENETIC SCREENING (Neil A. Holtzman & Michael S. Watson eds.,
1997), available at http://biotech.law.lsu.edu/research/fed/tfgt/index.htm#EXECUTIVE.
20. See CTR. FOR BIOETHICS, supra note 18, at 7 (noting that PKU can be controlled by diet);
Paul, supra note 19 (noting the rarity of PKU).
21. Paul, supra note 19.
22. Id.
23. Id.
24. See PRESIDENT'S COUNCIL ON BIOETHICS, supra note 16, at 7 (noting that, depending on
the state of birth, an infant will likely be screened for between 29 and 54 conditions).
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conditions. 25 Today, most states screen for all or nearly all of the 29 core
conditions.26
NBS programs "represent the most comprehensive population testing
program" in existence, with "specimens . .. obtained from essentially every
newborn" in the United States.27 Although educational pamphlets about the
screening program are typically distributed to the parent, guardian, or
managing conservator, (hereinafter "parent"), state statutes, almost
universally, do not require NBS programs to obtain the informed consent of
the newborn's parent prior to extracting the blood sample. 28
Informed consent, now widely codified into state medical practice
legislation, is firmly rooted common law concept that recognizes the right
of self-determination, and promotes individual autonomy in making
medical decisions concerning one's own body, as well as the bodies of
one's children. 29 It reflects the moral belief that physicians must not inflict
25. See Mary Ann Baily, Newborn Screening, in FROM BIRTH TO DEATH AND BENCH TO
CLINIC: THE HASTINGS CENTER BIOETHICS BRIEFING BOOK FOR JOURNALISTS, POLICYMAKERS,
AND CAMPAIGNS 125-28 (Mary Crowley ed., 2008), available at
http://www.thehastingscenter.org/uploadedFiles/Publications/BriefingBook/newborn%20screeni
ng%20chapter.pdf (listing core conditions and discussing ethical controversies in newborn
screening).
26. Id. at 125. Unlike PKU, some of these conditions have no effective treatments. See
Donald B. Bailey, Jr., The Blurred Distinction Between Treatable and Untreatable Conditions in
Newborn Screening, 19 HEALTH MATRIX 141, 141-42 (2009) (noting that new technologies allow
physicians to screen infants for conditions for which medical treatment is unavailable). Newborn
screening for conditions that are not presently treatable is highly controversial, and beyond the
scope of this article. For insight into the debate surrounding screening for currently untreatable
conditions, see generally Jeffrey R. Botkin, Assessing the New Criteria For Newborn Screening,
19 HEALTH MATRIX 163, 163-64, 181-83 (2009) (summarizing state newborn screening
programs, the expansion in the number of conditions being added to screening tests, and the
difficulties involved with adding new tests with the potential benefits are not yet being realized);
Ellen Wright Clayton, Ten Fingers, Ten Toes: Newborn Screening For Untreatable Disorders, 19
HEALTH MATRIX 199, 200-03 (2009) (discussing newborn screening for untreatable disorders
with the movie GATTACA and the various public policies such screening brings to society at
large); R. Rodney Howell, Systems to Determine Treatment Effectiveness In Newborn Screening,
19 HEALTH MATRIX 155, 156-57 (2009) (commenting on the various collaborative screening and
genetics groups around the United States that track newborn screening and the need for long-term
information sharing); Marvin R. Natowicz & Shlomit Zuckerman, On Treatability:
Considerations of Treatment In The Context of Newborn Screening, 19 HEALTH MATRIX 187,
189-93 (2009) (reviewing several newborn screening articles on the subjects of treatability,
general population screening and its implications, and the rising costs of screening tests).
27. Bradford L. Therrell et al., Status of Newborn Screening Programs in the United States,
117 PEDIATRICS S212, S213 (2006).
28. U.S. GEN. ACCOUNTING OFFICE, GAO-03-449, NEWBORN SCREENING:
CHARACTERISTICS OF STATE PROGRAMS 22 (2003), available at
http://www.gao.gov/new.items/d03449.pdf (noting that only Wyoming's statute requires consent
to screen a newborn bloodspot, and that regulations in Maryland also require consent to screen).
29. See, e.g., Schloendorff v. Soc'y of New York Hosp., 105 N.E. 92, 93 (N.Y. 1914) ("Every
human being of adult years and sound mind has a right to determine what shall be done with his
own body[.").
JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 14:299
medical procedures upon their patients against the patient's will. 30 The right
to informed consent, and the corresponding duty of the physician to obtain
that consent, is not absolute. Legally justified exceptions to the informed
consent requirement may exist in circumstances where the exception is
necessary for the benefit of the individual, or in the best interests of
society. 3i States, through their police power and by virtue of their duty to
promote the public welfare, may disregard informed consent requirements
where, for example, quarantine is necessary to prevent the spread of
infectious disease, or where mass vaccinations are required to control
epidemics. 32
NBS programs undoubtedly present an acceptable use of a state's
police power, and the need to implement these programs without the
informed consent of the parent may be justified to the extent the programs
are designed to identify newborns needing immediate medical care. More
recently, however, a disturbing trend has emerged. Some states have gone
beyond the original intent of their NBS programs, and have begun storing
the baby's blood samples indefinitely for future medical research
purposes.3 3 One study reveals that, although most states store blood for
reasons authorized by statute, such as quality assurance, twelve states retain
their blood samples without any officially stated reason. 34 Moreover, great
disparity exists among states in the length of time that the samples are
retained. As of 2009, South Dakota retains its samples for only one month,
but Indiana and New Jersey retain their samples for 23 years.35 Seven other
30. See BARRY R. FURROW ET AL., HEALTH LAW 230 (6th ed. 2008) ("Informed consent has
developed out of strong judicial deference toward individual autonomy, reflecting a belief that an
individual has a right to be free from nonconsensual interference with his or her person, and a
basic moral principle that it is wrong to force another to act against his or her will.").
31. See, e.g., RUTH B. FADEN & TOM L. BEAUCHAMP, A HISTORY AND THEORY OF
INFORMED CONSENT 35 (1986) (noting that there are five recognized informed consent
exceptions, including public health and medical emergencies, incompetency of the patient,
therapeutic privilege, and patient waiver).
32. See id at 35-36 (explaining that interventions by public health officials are authorized by
law in cases where the adoption of a mass health program is required for the health and safety of
an entire population, and that such interventions can include quarantine and mass vaccination
requirements).
33. See Aaron Joshua Bienstock Goldenberg, Ethics at the Crossroads of Public Health and
Biobanking: The Use of Michigan's Residual Newborn Screening Bloodspots for Research 7
(Nov. 19, 2008) (unpublished Ph.D. dissertation, Case Western Reserve University), available at
http://etd.ohiolink.edu/send-pdf.cgilGoldenberg%20Aaron.pdf~casel 228421146 (noting that
many states retain bloodspots after screening, and that a few store them indefinitely and regard
them as a "potentially rich source of readily available DNA samples for population based genetic
research").
34. Kenneth D. Mandl et al., Newborn Screening Program Practices in the United States:
Notification, Research, and Consent, 109 PEDIATRICS 269, 271 (2002).
35. CITIZENS' COUNCIL ON HEALTH CARE, STATE BY STATE GOVERNMENT NEWBORN
BLOOD & BABY DNA RETENTION PRACTICES 1-2 (2009), available at
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states store their samples "indefinitely." 36 A 2006 study revealed that 28
states had no written policy governing storage of residual newborn
bloodspots.37 Specimens that have been stored for more than a few months
are no longer satisfactory for confirmation of a newborn's screening results,
but the DNA contained in the bloodspot is stable indefinitely.38 Thus,
bloodspots stored longer than a few months are useful primarily for their
research potential.39
While it may be sensible in the context of a public health initiative to
screen newborns for genetic diseases without first obtaining the consent of
the parent, this justification does not extend to the subsequent retention and
use of the bloodspots for general medical research. When the purpose of
state NBS programs is not only for the benefit of the babies who are
screened, but also to establish a population-wide repository of baby's blood
for future genetic research, the issue becomes more complex. The
controversy over retention of baby's blood for future genetic research,
without the informed consent of the participants, is at the heart of the two
state lawsuits discussed below. The issues raised in the two lawsuits are
issues that all States will confront as public awareness regarding genetic
research on newborn bloodspots increases. These two lawsuits illustrate
how the public's trust in a state NBS program can be undermined by
discovery of the state's undisclosed genetic research activities.
II. THE LAWSUITS
A. Texas
Prior to this lawsuit, Texas had the largest baby's blood repository in
the country, with over five million stored samples. 40 The Texas Department
of State Health Services ("TDSHS") often provided blood samples to other
states, without any published guidelines addressing the type of research that
http://www.cchfreedom.org/pdf/50_States-NewbornBloodRetentionPolicies-FINAL.pdf
(providing sample retention data for all fifty states and the District of Columbia). The Council
used data compiled by the National Newborn Screening Information System (http://genes-r-
us.uthscsa.edu/). Id. at 3 nI.
36. Id. at 1-2. These states are: California, Maine, Michigan, Minnesota, North Carolina,
Tennessee, and Vermont. Id.
37. Therrell et al., supra note 27, at S219.
38. Id at S221.
39. Id at S221-22.
40. See Peggy Fikac, Infant Blood Samples to Be Discarded: State Agrees to Destroy Them
After Millions Kept Without Permission: Plaintiff Says She Wants Children's Privacy Respected,
Hous. CHRON., Dec. 23, 2009, at B (noting that the state of Texas will destroy 5.3 million
newborn bloodspots taken legally, but without parental consent, in settlement of lawsuit).
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could be conducted using the samples.4 1 Before the lawsuit, the state had
distributed newborn bloodspots for research projects ranging from various
University-sponsored disease studies, to the creation of a Department of
Defense-sponsored international database designed to aid in criminal
investigations and other forensic endeavors, and to for-profit companies'
development of more effective screening test-kits.42
Texas law requires all newborns to be screened for 29 core disorders
within 48 hours of birth, and again at the two-week newborn check-up. 43
Prior to recently passed legislation, parents could object to the screen only
if screening would conflict with their religious tenets. 44 Once the screening
was complete, the statute limited disclosure of any information related to
the screening to diagnosis and medical treatment, and to certain statistical
and record-keeping purposes.45 At the time the Texas lawsuit was filed, the
statute did not give the State the authority to retain the samples indefinitely;
rather, the statute was silent as to the disposition of the samples after
screening was complete, although another statute governing the
confidentiality of genetic information provided that samples obtained from
individuals for genetic testing must be "destroyed promptly after the
purpose for which the sample was obtained is accomplished," with only a
few narrow exceptions.46
The class action lawsuit was filed in the San Antonio Division of the
District Court for the Western District of Texas on March 12, 2009.47
Plaintiffs, represented by a Texas civil rights attorney, were representative
of their respective classes: a recent mother, a father of children born
between 2003 and 2007, a mother of children born between 1993 and 1998,
41. See Mary Ann Roser, State Agency Swaps Babies' Blood for Supplies, AMER.
STATESMAN, May 8, 2010, http://www.statesman.com/news/texas-politics/state-agency-swaps-
babies-blood-for-supplies-678302.html (reporting that Texas health officials' practice of
providing blood samples from newborns to out-of-state companies and researchers was halted so
that the state could develop policy relating to the handling of bloodspots).
42. See Use of Newborn Screening Blood Spots After Completion of Newborn Screening,
TEX. DEP'T OF ST. HEALTH SERVS. (Feb. 17, 2011),
http://www.dshs.state.tx.us/lab/nbsBloodspotsUse.shtm (disclosing previous research uses as part
of lawsuit settlement); see also Roser, supra note 41 (reporting on the non-screening uses to
which DNA obtained from bloodspots were put).
43. See 25 TEX. ADMIN. CODE § 37.53 (2011) (listing disorders for which newborn screens
are required).
44. TEX. HEALTH & SAFETY CODE ANN. § 33.012(a) (West 2010).
45. § 33.014 (governing disclosure of screening test results to certain physicians, parents, or
health authorities); see also § 33.015 (providing for the authority of health services department to
collect data to derive incidence and prevalence rates, and for other statistical and record-keeping
purposes).
46. TEx. OCC. CODE ANN. § 58.052 (West 2010).
47. Complaint, Beleno v. Texas Dep't of State Health Servs., No. 5:09-cv-00188-FB (W.D.
Tex. Mar. 12, 2009).
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the father of a baby born in January 2009, and a pregnant woman expecting
her first child in August 2009 (seeking, at the time, prospective relief).48
The Defendants were employees of the Texas Department of State Health
Services (TDSHS), sued in their official capacities and Texas A&M
University (the bloodspot storage facility) (collectively, the "State"). 49 The
Plaintiffs alleged that the State had exceeded its statutory authority to
conduct newborn screening for specific diseases, by wrongfully storing 4.2
million NBS samples since July 2002.50 Nothing in the Texas statute
authorized the state to store the samples, or to make them available for
future research unrelated to the NBS program. 51 And, Plaintiffs alleged, the
State acted secretly, and without the knowledge or consent of the parents. 52
The Plaintiffs sought declaratory and injunctive relief for violation of their
Constitutional rights under the Fourth (search and seizure) and Fourteenth
(liberty and privacy) Amendments to the U.S. Constitution, and their
corresponding state constitutional rights. 53 They also sought an injunction
ordering the State to disclose the purposes for which the children's blood
has been used and any financial transactions involved, and they sought the
destruction of the 4.2 million NBS samples retained by the State. 54
The State essentially admitted its practice of storing the bloodspots
indefinitely and using them for future research purposes, and acknowledged
its apparent lack of statutory authority. It defended this practice, however,
on the grounds that the bloodspots were lawfully taken (a claim that the
plaintiffs did not contest), and that any private genetic information derived
from the bloodspots that could conceivably give rise to plaintiffs'
constitutional privacy interest claims was protected by adequate security
measures. 55 Moreover, the State contended that the use of the bloodspots
48. See id at 2-3 (detailing relevant information about the plaintiffs); see also Peggy Fikac,
State to Destroy Blood Samples, SAN ANTONIO EXPRESS-NEWs, Dec. 23, 2009, at I B (reporting
on the outcome of the Beleno lawsuit, and noting that an attorney from the Texas Civil Rights
Project prosecuted the lawsuit).
49. See Complaint, supra note 47, at 3 (detailing relevant information about the defendants).
50. Id. at 5-6.
51. See id. at 4("Defendants, without any authority or legal justification, have added this
practice onto the state's 44 year-old mandated newborn screening program in which hospitals,
birthing centers, and midwives draw blood from a baby's heel - no parental consent is required -
so the state can test for a variety of birth defects.").
52. Id
53. Id. at 5-6.
54. Id. at 9.
55. Motion to Dismiss Plaintiffs' Original Complaint at 12-15, Beleno v. Texas Dept. of State
Health Servs., No. SA09CA0188-FB (W.D. Tex. May 29, 2009) (relying on Whalen v. Roe, 429
U.S. 589, 592-93 (1977) for the proposition that the state retention of private medical information
is not an unconstitutional invasion of privacy where the statute that allows the state to collect such
information also provided security measures for protection of the information in the state's
possession) (on file with author).
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for future medical research was governed by the federal HIPAA privacy
regulations, which specifically allow for the use and disclosure of protected
health information for research purposes once a later, specific, research
protocol has been analyzed and approved by an institutional review board
("IRB").56 With respect to the issue of informed consent, the State
contended that, at such time as the samples were used for a specific research
project, the federal regulations for the protection of human subjects in
medical research would determine the circumstances under which the
parent's informed consent would or would not be required. The State
rightfully pointed out that privacy concerns differ depending on whether the
human subject has been or could be identified from the information released
to the researchers. 57 If, the State argued, the regulations required the
parental consent for a specific future medical research protocol, that consent
could be obtained from the parent at that point in the future. 58
Barely eleven weeks into the lawsuit, and amidst a flurry of high
profile news articles about the pending lawsuit, 59 the Governor of Texas
signed into law an amendment to the states newborn screening statute.
House Bill No. 1672 plugged one gap in state law by giving the State
authority to retain and store the bloodspots, and to release de-identified 60
information relating to the bloodspots for medical research purposes,
provided the research had been approved by an IRB. 6 1
But the new legislation did not require the State to obtain the written
informed consent of the parents. Rather, the legislature instituted an "opt-
out," or presumed consent, system. The new system requires the physician
attending the newborn to disclose to the parent that the State could legally
retain and store the bloodspots, and could subsequently release the
bloodspot along with de-identified genetic information, for future research
purposes. 62 The physician must also provide the patient with a form that the
parent can use if she did not want the State to retain her child's genetic
material, or to use it for use it for any purpose outside of the newborn
56. Id. at 16.
57. Id. at 17.
58. Id.
59. See infra notes 188-194 and accompanying text.
60. De-identified information, also called coded or linked information, refers to data that are
"separated from personal identifiers through use of a code." See SEC'YS ADVISORY COMM. ON
HERITABLE DISORDERS IN NEWBORNS AND CHILDREN, HEALTH RES. AND SERV. ADMIN.,
CONSIDERATIONS AND RECOMMENDATIONS FOR NATIONAL GUIDANCE REGARDING THE
RETENTION AND USE OF RESIDUAL DRIED BLOOD SPOT SPECIMENS AFTER NEWBORN
SCREENING 13 (2010),
http://www.hrsa.gov/heritabledisorderscommittee/RBSBriefingPaperFlNALDraft423 I 0.pdf
61. H. R. 1672, 81st Leg. (2010), codifiedat TEX. HEALTH & SAFETY CODE ANN. § 33.0111
(West 2010) (requiring the disclosure statement).
62. TEX. HEALTH & SAFETY CODE ANN. § 33.011 1(aHc) (West 2010).
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screening test. 63 The statute does not require the physician who gives the
form to the mother-to-be to explain her rights or discuss her options, nor
does it require the provider to obtain the completed form from the parent
and return it to the State. Thus, the burden is wholly placed on the parent to
educate herself regarding her baby's participation in future genetic research,
and to complete the form and file it with the TDSHS. Once the Department
receives the form, the State has 60 days to destroy the child's genetic
material.64 Otherwise, the State will presume that the parent agrees to have
the State store her baby's bloodspot indefinitely, and to release it to outside
entities for genetic research.65
The new legislation encouraged settlement of the lawsuit, but not until
the State agreed to destroy the millions of newborn blood samples that it
had stored prior to adoption of the new law, and to publish a list of research
projects that had used the bloodspots for genetic research.66 Due to the
settlement, the court did not rule on whether informed consent was required
for future medical research on the bloodspots, or whether a presumed
consent system was adequate to protect the newborn. 67
63. § 33.0112 (a) (2010) (requiring that parents file a statement prohibiting retention of
genetic material).
64. §33.0112 (b).
65. See § 33.017 (c)(4) (providing that de-identified samples may be released for research
purposes without the consent of the parent).
66. News Release, Tex. Dept. of State Health Servs., Statement: Newborn Screening
Settlement (Dec. 22, 2009), available at http://www.dshs.state.tx.us/news/releases/20091222.shtm
("As a result of this settlement, DSHS will destroy all bloodspot cards received by the department
before May 27, 2009, the date legislation expressly authorized the storage and specified uses of
the samples."); see also Peggy Fikac, State to Destroy 4 Million Newborn Blood Samples,
HOUSTON CHRON., Dec. 22, 2009 available at
http://www.chron.com/disp/story.mpl/metropolitan/6782897.html ("The state will destroy an
estimated 5.3 million blood samples legally collected from newborns but kept without parental
consent under a federal lawsuit settlement announced Tuesday."); Nanci Wilson, Government
Taking Newborn DNA Samples: Many Ask Why They Are Saving the Samples, KXAN AUSTIN
NEWS, Nov. 24, 2009, available at http://www.kxan.com/dpp/health/government-taking-
newborn-dna-samples (reporting that the lawsuit prompted a bill in the Texas legislature allowing
the state to keep and use blood samples for research only if parents are informed and given the
option of having their child's leftover samples destroyed after screening).
67. Update on the Texas litigation: A second lawsuit was filed on December 8, 2010 claiming
that during the settlement negotiations on the first lawsuit, the Defendant, Texas Department of
Health Services, "knowingly and deceptively" withheld certain information from the Plaintiffs.
Specifically, the lawsuit alleges that the State lied about whether or not they had ever distributed
or sold blood samples to other state or federal agencies or private companies. The Plaintiffs claim
that the State gave newborn blood samples to private companies in exchange for a fee or various
lab and testing equipment, and that the State also distributed blood samples to the Armed Forces
Institute of Pathology, although the State had earlier denied doing so. Complaint, Higgins v. Texas
Dept. of State Health Servs., No. 5:10 -cv-00990 (W. D. Tex 2010) (on file with author). The case
has been set for trial August 6, 2012.
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B. Minnesota
Two apparently conflicting statutes are at the heart of the Minnesota
lawsuit: (1) the State's Newborn Screening statute ("NBS statute") 68 and
(2) the Minnesota Genetic Privacy Act ("GPA").69 The NBS statute
describes the Minnesota NBS Program, and allows the state to store
indefinitely the bloodspots, but gives parents two alternative choices: (1)
they may refuse the test, or (2) they may have the test but elect to have the
blood samples and test records destroyed within 24 months of the testing.70
The NBS statute does not require written parental informed consent; rather
it is similar to the post-settlement Texas presumed consent statute that
places the burden on the parent to object in writing.
In 2005, the Minnesota legislature directed the state health department
to review the law governing the state's handling of genetic information. The
health department recommended that the legislature be asked to create a
definition for genetic information, and to give guidance on the collection,
storage, use, and dissemination of genetic information not already
addressed by existing law.71 Subsequently, in 2006, the Minnesota
legislature passed the GPA. The GPA defined "genetic information" as
information about an identifiable individual derived from the presence,
absence, alteration, or mutation of a gene, or the presence or absence of a
specific DNA or RNA marker, which has been obtained from an analysis
of . .. the individual's biological information or specimen . . . ."72
Germaine to the subsequent lawsuit, the GPA allowed a government entity
to "collect genetic information only with the written informed consent of
the individual," and provided that the information could be used, stored,
and disseminated only in accordance with the individual's written informed
consent.73 In 2007, an administrative law judge report addressed certain
proposed amendments to the newborn screening rules. The administrative
court considered whether the GPA applied to genetic information collected
under the NBS Program. 74 It found that, although the initial collection of
the bloodspot is authorized by the NBS statute, the State had no statutory
support for its practice of retaining the samples indefinitely without the
consent of the parent, and that the opt-out nature of the initial screening
68. MINN. STAT. ANN. § 144.125 (2003).
69. MINN. STAT ANN §13.386 (West Supp. 2011).
70. MINN. STAT. ANN. § 144.125.
71. See Order Granting Motion to Dismiss at 5, Bearder v. Minn., No. 27-CV-09-5615 ( 4th
Dist. Nov. 24, 2009), available at 2009 WL 5454446.
72. MINN. STAT. ANN. § 13.386 Subd. 1(a) (2011).
73. § 13.386 Subd. 3.
74. Proposed Amendments to Rules Governing Newborn Screening, Minnesota Rules,




was insufficient to support the State's practice. 75 Furthermore, the court
found no statutory support for the State's dissemination of screening
information to third party researchers. 76 The court concluded that the GPA
did apply to the NBS rules, and the State's proposed amendments to the
NBS Program were defective because they did not incorporate the
requirements of the GPA.7 7 The administrative findings were reviewed and
confirmed by the Chief Administrative Law Judge78
On March 11, 2009, one day before the Texas lawsuit was filed, and
after the encouraging administrative developments described above,
seventeen parents representing nine families, filed suit in Minnesota state
court. The Plaintiffs alleged that the State was in violation of its GPA
because it used, indefinitely stored, and disseminated for outside research,
the de-identified bloodspots and test information obtained pursuant to the
State's NBS Program, without the written informed consent of the parents,
as required by the GPA. 79 The State filed its motion to dismiss on the
grounds that the GPA only protects genetic information. Bloodspots, it
argued, were just blood, and not data or information obtained from the
analysis of a biological specimen, as required by the GPA's definition of
genetic information.80 The Plaintiffs countered, asserting that only one
purpose existed for the State's warehousing of the specimens-the future
extraction of genetic information from the DNA located within the
75. Id. at 21; see also id. at 17 (finding that "parents are not informed that the Department
will maintain the test results for an indefinite period of time; that the parents may decide later to
request that the blood sample and test results be destroyed; or that the blood sample may be
provided to outside institutions for research purposes").
76. Id. at 21. (finding that "[t]here is no express authorization in the newborn screening
statute for the Department's current practice of retaining the information indefinitely without
consent and permitting the information to be used without consent for purposes other than the
detection, treatment, and follow-up of heritable and congenital disorders as contemplated by the
newborn screening statute").
77. Id. at 19, (finding that "a parent or guardian must receive all of the information required
by [the Generic Privacy Act] before the screening test is done and before the parent or guardian
decide whether to "opt out" of the information retention scheme").
78. See Order Granting Motion to Dismiss at 6, Bearder v. Minn. No. 27-CV-09-5615 (Trial
order Nov. 24, 2009), available at 2009 WL 5454446 (noting that the ALJ report was reviewed
and confirmed by the Chief Administrative Law Judge).
79. See Plaintiffs Mem. of Law at 1-2, 6-7, 17, Bearder v. Minn., No. 27-CV-09-5615 (4h
Dist 2009), available at 2009 WL 5427609.
80. Id. at n. 97 (referencing Def. Mem. of Law at p. 17, n. 13); see also MINN. STAT. ANN. §
13.386 Subd.l(West Supp 2011) (defining "genetic information" as "information about an
identifiable individual derived from the presence, absence, alteration, or mutation of a gene, or the
presence or absence of a specific DNA or RNA marker, which has been obtained from an analysis
of: (1) the individual's biological information or specimen; or (2) the biological information or
specimen of a person to whom the individual is related").
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bloodspot; therefore, the mere storage of the bloodspots is constructively
the use of "genetic information" as defined by the GPA. 81
The state court judge agreed with the State, rejecting out of hand the
reasoning of the administrative court, and granting the State's motion to
dismiss the lawsuit. The court found that the screening samples were "not
genetic information as defined in the GPA," but that even if they were, the
"GPA did not supersede the provisions of the NBS Program." 82 The court
reasoned that the Plaintiffs had the choice to request in writing that their
samples not be stored indefinitely. The Court of Appeals affirmed the trial
court, but the Minnesota Supreme Court granted the Plaintiffs Petition for
Further Review on November 16, 2010.83 At this writing, the case remains
pending before the State's high court.
In both of the lawsuits described above, the state argued that the
bloodspots and their accompanying information were coded to protect
individual privacy, and no information would be released to outside
researchers unless the research had been approved by an IRB, as required
by federal regulations. What the lawsuits failed to consider, however, is
whether the act of establishing a bloodspot research biobank was, in and of
itself, medical research. Neither of the lawsuits described above considered
whether the federal regulations for the protection of human research
subjects, or federal guidance for establishing tissue repositories for research
purposes, applied to NBS programs. Had they done so, they may have
found that the law requires the written, informed consent of the parent
before biobanking newborn blood for subsequent research purposes.
III. ARE THE FEDERAL PROTECTIONS FOR RESEARCH SUBJECTS RELEVANT
TO STATE NBS PROGRAMS?
The federal protections for human research subjects are today codified
in Title 45, Part 46 of the Code of Federal Regulations. Of prime
importance is the recognition that the informed consent of research
participants is absolutely essential.84 To place in context the important role
of informed consent in medical research, a brief history of these federal
regulations is necessary.
The federal regulations governing research on human subjects grew
out of a disturbing set of historical events, and at a time when medical
research was at best secretive and unregulated, and, at worst, inhumane.
81. Plaintiffs Mem. of Law, supra note 79 at 23.
82. Order Granting Motion to Dismiss, supra note 78.
83. Bearder v. Minn., 788 N.W.2d 144, 152 (Minn. Ct. App. 2010).
84. See 45 C.F.R. § 46.117 (2009) ("informed consent shall be documented by the use of a
written consent form approved by the IRB and signed by the subject or the subject's legally
authorized representative. A copy shall be given to the person signing the form.").
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The principle of informed consent developed in response to the atrocities
committed by Nazi doctors and scientists under the guise of medical
research during World War II, and the subsequent 1946 Nuremberg
Military Tribunal that brought these war criminals to justice. 85 Part of the
tribunal's decision included what has become known as the Nuremberg
Code. 86 The Nuremberg Code was drafted during the War Crime Tribunals
as a set of principles, or standards, for judging those physicians and
scientists who had conducted medical experimentation on concentration
camp prisoners.87 The first principle of the Nuremberg Code is "[t]he
voluntary consent of the human subject is absolutely essential." Medical
research practice in the United States, however, was surprisingly unchanged
by the Nuremberg Trials and the ensuing world attention on the use of
humans in medical research. The medical research community was hard
pressed to believe that the rules arising out of Nazi atrocities could possibly
relate to their research. It was not until 1966, when a highly controversial
article by Dr. Henry K. Beecher provided twenty-two examples of
unethical medical research published in leading medical journals, that the
federal government focused on the need for regulation.89 The public
awareness of injustice and unethical research followed in 1972 when a
reporter for the New York Times broke the story of the so-called Tuskegee
Study, where it was revealed that the United States Public Health Service
had conducted a forty-year long study of syphilis, using over 400 poor
black sharecroppers from Alabama as subjects to study the progress of the
disease. 90 The Government did not obtain consent from the men, nor were
the men told that they had any disease other than "Bad Blood," although the
government promised that the men would receive treatment for their
85. See, Jay Katz, The Consent Principle of the Nuremberg Code: Its Significance Then and
Now, in THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN
EXPERIMENTATION 227, 227-228 (George J. Annas & Michael A. Grodin eds., 1992).
86. Id.
87. Michael A. Grodin, Historical Origins of the Nuremberg Code, in THE NAZI DOCTORS
AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 121, 137-38
(George J. Annas & Michael A. Grodin eds., 1992).
88. Nuremberg Code, in 2 TRIALS OF WAR CRIMINALS BEFORE THE NUREMBERG MILITARY
TRIBUNALS UNDER COUNTROL COUNCIL No. 10, 181-82 ( 1949), available at
http://ohsr.od.nih.gov/guidelines/nuremberg.html. This principle was modified in 1964 by the
Declaration of Helsinki, which allows a legally authorized representative to consent for legally
incompetent persons who are physically or mentally incapable of giving consent. Declaration of
Helsinki: Ethical Principles for Medical research Involving Human Subjects,WORLD MEDICAL
ASSOCIATION (1964), available at http://ohsr.od.nih.gov/guidelines/helsinki.html.
89. Henry K. Beecher, Ethics in Clinical Research, 274 NEW ENG. J. MED. 1354, 1355-1359
(1966).
90. Jean Heller, Syphilis Victims in US. Study Went Untreatedfor 40 Years, N.Y. TIMES, July
26, 1972, at 1,8.
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condition. 91 The men did not receive any treatment and, most shocking,
even after penicillin therapy became available to treat the disease, these
men were not offered the treatment. Rather, the goal of the government
program was to follow the men to their deaths, and through autopsy,
continue research on syphilis. 92
Following this revelation, the Food and Drug Administration ("FDA")
and the National Institutes of Health ("NIH") developed internal guidelines
providing rudimentary subject protections that were codified as federal
regulations in 1974.93 At the same time, the newly formed National
Commission for the Protection of Human Subjects of Biomedical Research
and Behavioral Research ("National Commission") was given the task of
identifying the ethical principles underlying biomedical research involving
human subjects and instructed to develop federal guidelines. 94 Among the
seventeen reports produced by the National Commission was the Belmont
Report. This report provided a framework for solving the ethical problems
that arise in human subject research, and it is the Belmont Report that is the
basis for the current federal regulations governing the protection of human
research subjects.
The Belmont Report identified and explained three fundamental
ethical principles necessary for the protection of human subjects in medical
experimentation: (1) respect for persons; (2) beneficence; and (3) justice.95
The requirement for informed consent arises out of the ethical principle of
respect for persons. According to the Belmont Report:
Respect for persons incorporates at least two ethical
convictions, first, that individuals should be treated as
autonomous agents, and second, that persons with
diminished autonomy are entitled to protection. The
principle of respect for persons thus divides into two
separate moral requirements: the requirement to
acknowledge autonomy and the requirement to protect
those with diminished autonomy. 96
91. JAMES H. JONES, BAD BLOOD: THE TUSKEGEE SYPHILIS EXPERIMENT 5 (expanded ed.
1993).
92. Id. at 138.
93. Harold Y. Vanderpool, Introduction and Overview: Ethics, Historical Case Studies and
the Research Enterprise, in THE ETHICS OF RESEARCH INVOLVING HUMAN SUBJECTS FACING
THE 21" CENTURY 1, 10 (Harold Y. Vanderpool ed. 1996).
94. See William J. Winslade & Todd L. Krause, The Nuremberg Code Turns Fifty, in ETHICS
CODES IN MEDICINE: FOUNDATIONS AND ACHIEVEMENTS OF CODIFICATION SINCE 1947, 150
(Ulrigh Trohler & Stella Reiter-Theil eds., 1996).
95. See The Belmont Report: Ethical Principles & Guidelines for Research Involving Human
Subjects, 44 Fed. Reg. 23,192, 23,193-194 (Apr. 18, 1979), available at
http://www.hhs.gov/ohrp/policy/belmont.html.
96. Id. at 23,193.
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The Belmont Report stressed the importance of distinguishing between
medical practice and medical research, warning that the line between
practice and research is blurred because often both occur together. 97
Practice is designed for the well-being of the patient, and the physician
diagnoses and treats her patient accordance with methods that have a
reasonable expectation of success. Research, on the other hand, is designed
to test a theory, or hypothesis, that will, hopefully, benefit society in the
future. 98 Thus, the term "subject" is used to denote one who participates in
research, as opposed to the "patient" who is treated for an illness. 99
In the context of newborn screening, the original purpose of NBS
programs was only to discover, diagnose, and treat the baby born with a
heritable disease-a process that was solely for the benefit of the baby. On
the other hand, a newbom who gives blood for medical research purposes
has no such expectation of individual benefit. The bloodspot will be
biobanked and disseminated in the future to investigators for genetic
research that will one day, hopefully, benefit society at large. The newbom
is, at the same time, the "patient" being screened for heritable diseases, and
the "subject" of genetic research. To the extent that the newborn is a
"research subject," as discussed infra, 00 the ethical precepts as expressed
in the Belmont Report, and today in the federal regulations, would require
written informed consent prior to bloodspot collection.
A. Are State Newborn Screening Programs "Conducted or Supported" by a
Federal Department or Agency?
The Federal Regulations for Human Subject Protection, 10 1 also known
as the Common Rule, 102 apply only to "research involving human subjects
conducted, supported or otherwise subject to regulation by any federal
department or agency."10 3 State NBS programs are regulated by state public
97. Id.
98. Id. Medical ethicist Jay Katz notes that it is "imperative to view clinical research as a
distinct category, sharply delineated from clinical practice." Jay Katz, Human Experimentation
and Human Rights, 38 ST. Louis U. L. J. 7, 17 (1993).
99. Katz, supra note 98 at 17 (noting that it is "imperative to view clinical research as a
distinct category, sharply delineated from clinical practice").
100. See infra Part Ill.B.
101. Protection of Human Research Subjects, 45 C.F.R. §§ 46.101-46.505 (2009).
102. Seventeen federal agencies responsible for funding or engaged in research have adopted
verbatim the human subject protections set forth in the Code of Federal Regulations. Russell
Korobkin, Buying and Selling Human Tissues for Stem Cell Research, 49 ARIZ. L. REV. 45, 52
n.37 (2007). Thus, it is called the Common Rule. Research that is subject to the Common Rule
must be reviewed by an Institutional Review Board (IRB). The IRB is responsible for assuring
that proper informed consent is obtained from the subjects who will participate in the research. 45
C.F.R. §§ 46.111 (a)(4)-(5) (2009).
103. 45 C.F.R. § 46.101 (a).
2011] 315
JOURNAL OF HEALTH CARE LAW & POLICY [VOL. 14:299
health departments. As such, they have not traditionally been viewed as
subject to the federal regulations for the protection of human subjects. The
federal imprint has become significantly more visible, however, with the
increasing state practice of storage and use of newborn screening samples
for genetic research. In a general sense, federal support is also evident in a
recent major national guidance document aimed at creating uniformity in
the storage and research use of newborn bloodspots.104 Applying the
federal human subject protections to state NBS programs would assure that
voluntary, informed consent is obtained from all parents before their child's
bloodspot is used for research that is not directly related to the screening
program.105
The federal government's regulations that protect human subjects
ought to apply to state NBS programs because the federal government,
primarily through the Department of Health and Human Services
("DHHS"), is inextricably intertwined with state NBS programs through its
direct financing of these programs, and indirectly through DHHS, NIH, and
other federal programs. For example, fully one-third of all births are
financed by Medicaid, the federal-state health insurance program for
eligible low-income individuals, and newborn screening is a Medicaid
covered service.106 State laboratories that analyze newborn bloodspots must
meet the regulatory requirements established by the Clinical Laboratory
Improvement Amendments of 1988 ("CLIA").10 7 If state laboratories fail to
meet CLIA requirements, they are subject to denial of Medicaid
payments.' 08 The Health Resources and Services Administration
("HRSA"), a federal agency that collects information on state NBS
104. HEALTH RES. AND SERVS. ADMIN., SEC'YS ADVISORY COMM. ON HERITABLE
DISORDERS IN NEWBORNS AND CHILDREN, CONSIDERATIONS AND RECOMMENDATIONS FOR
NAT'L GUIDANCE REGARDING THE RETENTION AND USE OF RESIDUAL DRIED BLOOD SPOT
SPECIMENS AFTER NEWBORN SCREENING 33 (2010), available at
http://www.hrsa.gov/heritabledisorderscommittee/RBSBriefingPaperFINALDraft423 0.pdf.
105. The Federalwide Assurance (FWA). All institutions engaged in non-exempt human
subject research that is conducted or supported by any HHS Agency must be covered by an Office
for Human Research Protection (OHRP) approved assurance of compliance, called a Federal Wide
Assurance. Under an FWA, an institution (or state) commits that it will comply with the federal
human subject requirements, including informed consent requirements, as set forth in 45 C.F.R.
Part 46. The FWA also means that other federal agencies may rely on the FWA for the research
they conduct or support. See generally, Federalwide Assurance for the Protection of Human
Subjects, U.S. DEP'T OF HEALTH & HUMAN SERVS.,
http://www.hhs.gov/ohrp/assurances/assurances/filasurt.htmi.
106. U.S. GOVT ACCOUNTABILITY OFFICE, GA- 03-449, NEWBORN SCREENING:
CHARACTERISTICS OF STATE PROGRAMS 5-6 (2003), ("The Centers for Medicare & Medicaid
Services' (CMS) involvement in newborn screening relates to its Medicaid and CLIA programs. ..
Medicaid finances services for one in three births each year.").
107. Id. at 3.
108. Id. at 7.
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programs, offers block grants to states to support their newborn screening
services. 109 The Newborn Screening Saves Lives Act of 2007 orders the
creation of a National Contingency Plan for Newborn Screening to assure
program continuation in the event of a public health emergency. 110 The
Contingency Plan is to ensure continuation of the NBS Program, as well as
"carrying out other activities determined appropriate by the Secretary,"
which could include subsequent genetic research programs."' The
Newborn Screening Saves Lives Act of 2007 authorizes over $5,000,000
per year to assist "laboratories involved in screening newborns and children
for heritable disorder" for various program integrity purposes. 12 Moreover,
the newly established Hunter Kelly Newborn Screening Research Program
authorizes the government to expand genetic research in newborn
screening, to develop new screening technologies, expand the number of
conditions for which screening tests are available, and "other genetic,
metabolic, hormonal and or functional conditions that can be detected
through newborn screening for which treatment is not yet available."' 13
Entities receiving funding through the program must assure the government
that they will "work in consultation with the appropriate State departments
of health. 114 In conducting the genetic research described above, the
newborn bloodspot repositories are indispensable. The federal protections
for human subjects ought to apply, given that at least a portion of the
federal money supporting NBS Programs is used to collect, analyze, and
store newborn bloodspots for future research purposes.
Moreover, the government has historically supported state NBS
programs indirectly through policy guidance. In 1985, HRSA funded
development of the Council of Regional Networks for Genetic Services
("CORN") to centralize information concerning the public health aspects of
genetic services. "' In 1996, CORN's Newborn Screening Committee
published Guidelines for the Retention, Storage, and Use of Residual Dried
Blood Spot Samples after Newborn Screening Analysis: Statement of the
Council of Regional Networks for Genetic Services.116 The stated purpose
109. Id. at 3,5. Federal grants include the Maternal and Child Health Services Block Grant for
newborn screening services support. Id. at 5.
110. Newborn Screening Saves Lives Act of 2007, Pub. L. No.110-204, sec. 7, § 1115, 122
Stat. 705, 711(2008)
Ill. Id. at sec. 7,§ I115(b)(8).
112. Id. at sec. 6, § 1113 (authorizing over $5,000,000 for fiscal years 2009 through 2013 to
newborn screening laboratories for quality assurance and performance evaluation).
113. Id. at sec. 7, § I 16(a)(1).
114. Id. atsec. 7,§ I116 (b).
115. U.S. GoVT ACCOUNTABILITY OFFICE, supra note 106, at 5..
116. Bradford L. Therrell et al., Guidelines for the Retention, Storage, and Use of Residual
Dried Blood Spot Samples After Newborn Screening Analysis: Statement of the Council of
Regional Networks for Genetic Services, 57 BIOCHEMICAL AND MOLECULAR MED. 116 (1996).
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of the paper was "to provide scientific information for policy development
by state health departments."1 7 In 1999, CORN was replaced by the
National Newborn Screening and Genetics Resource Center ("The Resource
Center"), a cooperative agreement between HRSA's Maternal and Child
Health Bureau and the University of Texas Health Science Center
Department of Pediatrics. 118 The government's most recent endeavor to
shape state newborn screening policy is its 2010 briefing paper produced by
the Secretary's Advisory Committee on Heritable Disorders in Newborns
and Children, titled "Considerations and Recommendations for National
Guidance Regarding the Retention and Use of Residual Dried Blood Spot
Specimens after Newborn Screening" ("2010 SACHDNC Draft National
Guidance").' 19
Given that the federal government has directly and indirectly
supported state newborn screening programs, as described in detail above,
the federal human subject protections ought to apply to genetic research
arising directly from those programs.
B. Do NBS Programs Involve Human Subject Research?
The federal regulations apply only to research conducted on human
subjects. The federal regulations define research as "a systematic
investigation . . . designed to develop or contribute to generalizable
knowledge."' 20 Research using newborn DNA, then, is designed to advance
genetic research so that society as a whole may benefit in the future, and not
for the individual benefit of the baby who supplies the blood. Thus,
collection of newborn bloodspots for research purposes is "research" under
the federal regulatory definition.
Moreover, the federal regulations apply only if the research involves
"human subjects." The Minnesota state court viewed a newborn bloodspot
as merely a biological sample, and not as human being's identifiable
genetic information deserving of legal protection. In both lawsuits
described above, the states argued that because the sample and test results
were de-identified before being disseminated for outside research, they
could not reasonably be connected to any individual; thus, "human
subjects" were not involved, and parental consent was not required.
According to the federal regulations, however, a "human subject" is "a
living individual about whom an investigator (whether professional or
117. Id. at 116.
118. U.S. GoVT ACCOUNTABILITY OFFICE, supra note 106, at 6; see also The National
Newborn Screening and Genetics Resource Center, http://genes-r-us.uthscsa.edu/ (last visited
May 25, 2011).
119. HEALTH RES. AND SERVS. ADMIN., supra note 104, at ii.
120. Protection of Human Research Subjects, 45 C.F.R. § 46.102(d) (2009)..
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student) conducting research obtains (1) data through intervention or
interacting with the individual, or (2) identifiable private information. 121
And, "intervention" includes physical procedures by which data are
gathered, such as venipuncture for blood collection. 122 Thus, the process of
obtaining the blood from the newborn, and attaching that bloodspot to the
Guthrie card, may meet the federal definition of research on a "human
subject." The physician interacts with the newborn to obtain the blood
containing the baby's valuable DNA, and the Guthrie card contains
identifiable private information about the baby and the mother that will be
biobanked for future genetic research purposes. In essence, within state
NBS programs, the newborn is at the same time, a "patient" being screened
for genetic diseases for the baby's personal benefit, and a "human subject"
involved in research. Given the basic premise that the baby's blood is
drawn for the dual purposes of screening and medical research, the federal
regulations regarding the protection of human subjects ought to be observed
at, or prior to, the point of blood collection. The written, informed consent
of the subject-here, the parent or guardian of the newborn, ought to be
obtained.
C. Does Newborn Bloodspot Biobanking Qualify for an Exemption or a
Waiver from the Federal Regulations?
Certain categories of research activities are exempt from federal
regulations, and do not require informed consent. One exempt category is
research conducted on already-existing diagnostic or pathological
specimens collected for clinical care (and not research) purposes, if the
information is recorded such that "subjects cannot be identified, directly or
through identifiers linked to the subjects." 123 In this vein, the Minnesota
trial court opinion characterized the newborn bloodspots as mere
"biological samples," and found that parental informed consent was
unnecessary because the samples were de-identified prior to being
disseminated for research. 124
121. 45 C.F.R. § 46.102(f).
122. Id. "Venipuncture" is the "surgical puncture of a vein." MILLER-KEANE ENCYCLOPEDIA
& DICTIONARY OF MEDICINE, NURSING, & ALLIED HEALTH 1 5 9 7 (5h ed. 1992).
123. 45 C.F.R. § 46.101 (b)(4) (exempting from federal policy: "Research, involving the
collection or study of existing data, documents, records, pathological specimens, or diagnostic
specimens, if these sources are publicly available or if the information is recorded by the
investigator in such a manner that subjects cannot be identified, directly or through identifiers
linked to the subjects.");see also Katherine Drabiak-Syed, State Codification of Federal
Regulatory Ambiguities in Biobanking and Genetic Research,30 J. LEGAL MED. 299, 300 (2009)
(noting that anonymous samples with no identifying information are not covered by the federal
regulations).
124. Order Granting Motion to Dismiss, supra note 71, at 4, 10.
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The federal regulatory exemption should not apply to NBS sample
collection for three reasons. First, this exemption presupposes that the
samples are collected initially in the course of diagnosis or treatment of a
known or suspected medical condition, and that, for subsequent research
purposes, they are already-existing pathological specimens. To the
contrary, the bloodspots are collected as part of a population-wide
screening and research program. The basic premise of this article is that,
today, and increasingly in the future, newborn screening has two distinct
purposes, one of which is to establish a bloodspot biobank for use in
conducting future genetic research. A 2004 OHRP guidance document
defines "existing" as "existing before the research is proposed to an
institutional official or the IRB .... "25 Although no specific research
protocol exists at the time of bloodspot collection, one purpose of bloodspot
collection and storage is for future genetic research. 126 Viewed in this light,
it seems disingenuous to claim that these biobanked bloodspots were
"already existing" clinical specimens entitled to exemption from informed
consent requirements. Second, the federal exemption applies only to
specimens that "cannot be identified, directly or through identifiers linked
to the subjects."' 27 The bloodspot, however, is affixed to the Guthrie card,
which contains the baby's and mother's identifying information. According
to a 2002 study, all except two of the 36 state NBS programs studied stored
their newborn bloodspots with the identifying information present.128 And,
even though the samples are coded (de-identified) before being
disseminated to outside researchers, they are not anonymous, and can be re-
identified if necessary. Third, the statutory exemption was enacted long
before the explosion of scientific advances in genotyping and genetic
sequencing wrought by the Human Genome Project.129 In that respect, the
general application of the exemption to biobanks is outdated. 130
Finally, newborn bloodspot collection and storage would not be
eligible for a waiver of informed consent under the federal regulations. An
IRB may waive informed consent requirements for certain low-risk
125. OFF. FOR HUMAN RESEARCH PROTECTION, HUMAN SUBJECT REGULATIONS DECISION
CHARTS Chart 5 (Sept. 24, 2004), available at
http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html.
126. Mark A. Rothstein, Expanding the Ethical Analysis of Biobanks, 33 J.L. MED. & ETHICS
89, 89 (2005).
127. 45 C.F.R. §46.101 (b)(4).
128. Kenneth D. Mandl et al., Newborn Screening Program Practices in the United States:
Notification, Research, and Consent, 109 PEDIATRICS 269, 271 (2002).
129. Lori B. Andrews, Harnessing the Benefits of Biobanks, 33 J.L. MED. & ETHICS 22, 24
(2005) (quoting Charles MacKay and Gerald S. Schatz, The Unfinished Research Agenda,
Address to the Nat'l Insts. of Health Inter-Ins. Bioethics Internet Group (June 7, 2004)).
130. See Andrews, supra note 129, at 24 (noting that the federal statutory exemption "was
adopted long before the advent of widespread genotyping and genetic sequencing").
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research if the research cannot be done unless the informed consent
requirement is waived. In order for a researcher to obtain a waiver, she must
show that "the research could not practicably be carried out without the
waiver."l 31 For example, an IRB may grant a waiver for a large-scale
epidemiological study using medical records spanning a significant time
period. 132 Obtaining informed consent from all of the patients under these
circumstances would be very difficult if not impossible to do. In the context
of newborn screening, however, a physician-patient relationship already
exists between the physician and the mother-to-be, and it is typically the
physician that is responsible for obtaining the bloodspot for screening and
research; thus, no barrier exists that would prevent the physician from also
obtaining proper informed consent for bloodspot storage and future
research. To the contrary, it is quite "practicable" for the provider to obtain
informed consent from the mother-to-be.
Even in cases of exempt research, or where the research may be
eligible for a waiver, many institutions still obtain consent from donors
whenever possible.133 This is likely so because institutions are aware that
scientific advances in the field of genetics have left the public concerned,
and even suspicious, about the nonconsensual use of their genetic
information. Genetics professor and scholar, Ellen Wright Clayton, in her
article Patients and Biobanks, notes that health care institutions recognize
that:
[N]on-disclosure and lack of oversight are risky in terms of
public perception. It is hardly as if the American public is
universally enthusiastic about its hospitals and clinicians.
The health care system is under fire from a number of
directions, from concerns that too many people are falling
through the cracks or being bankrupted to allegations of
fiscal mismanagement, fraud, and poor quality of care. As
part of this sea of concerns, health care institutions know
that at least some patients are concerned about how
131. 45 C.F.R. § 46.116(d) (providing that an IRB may either waive or alter the informed
consent requirement if "(1) the research involves no more than minimal risk to the subjects; (2)
the waiver or alteration will not adversely affect the rights and welfare of the subjects; (3) the
research could not practicably be carried out without the waiver or alteration; and (4) whenever
appropriate, the subjects will be provided with additional pertinent information after
participation") See also Sandra J. Carnahan, Promoting Medical Research Without Sacrificing
Patient Autonomy: Legal and Ethical Issues Raised by the Waiver of Informed Consent for
Emergency Research, 52 OKLA. L. REv. 565, 567 (1999).
132. CARL H. COLEMAN ET AL., THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN
SUBJECTS 313 (2005).
133. See Ellen Wright Clayton, Patients and Biobanks, 51 VILL. L. REv. 793, 796-97 (2006)
(noting that even projects that are technically exempt under OHRP guidance and other legal
regulations, many institutions still obtain consent).
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information about them and specimens from them are
used. 134
Given that the newborn bloodspot is collected for the dual purpose of
diagnosis and research, and that it is linked with identifying information
when it is biobanked, federal regulations, and federal guidance for
establishing research repositories would require parental informed consent.
Only written informed consent can fully protect research subjects, and
maintain the public trust in NBS programs.
IV. INFORMED CONSENT FOR PROSPECTIVE RESEARCH
Human tissue repositories collect, store, and distribute human tissue
and other biological material for research purposes. If the biological
material in the repository contains at least traces of DNA or RNA that
would allow genetic analysis, it is typically termed a "biobank," 135
although the terms "repository" and "biobank" are often used
interchangeably. When biobanks, such as the newborn bloodspot biobanks,
are established for future, long-term research use, they are known as
"prospective" biobanks. One difficulty with prospective biobanks is that, at
the time samples are collected, it is difficult to anticipate the specific future
use of the samples; thus, informed consent policy for biobank collection is
difficult to formulate. 136
The 2010 SACHDNC Draft National Guidance recognizes that
"[s]ome form of consent or formal IRB waiver of consent appears to be
necessary if newborn screening specimens are to be placed into a repository
for research purposes since creation of a research repository is, in and of
itself research."1 37 The Office for Human Research Protection ("OHRP"),
formerly the Office for Protection from Research Risks, has published
guidance for the collection, storage, and research use of stored data or
tissues, and provides a possible model for newborn blood spot biobanks:
Operation of the Repository and its data management
center should be subject to oversight by an Institutional
Review Board (IRB). The IRB should review and approve
a protocol specifying the conditions under which data and
specimens may be accepted and shared, and ensuring
adequate provisions to protect the privacy of subjects and
134. Id. at 802.
135. See Bernice S. Elger & Arthur L. Caplan, Consent and Anonymization in Research
Involving Biobanks 7 EMBO REPORTS 661, 661 (2006) (noting that the term "biobank" often
refers to "any collection of human biological material ... that contains at least traces of DNA or
RNA that would allow genetic analysis").
136. See id. at 663.
137. HEALTH RES. AND SERVS. ADMIN., supra note 104, at 12-13 (emphasis added).
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maintain the confidentiality of data. The IRB should also
review and approve a sample collection protocol and
informed consent document for distribution to tissue
collectors and their local IRBs. 138
The above model would be appropriate for establishing state research
repositories for newborn bloodspots, including IRB review and approval of
an informed consent document to be given to the parent a reasonable time
before birth. According to federal guidelines, the tissue collector is required
to obtain the informed consent of the donor when tissue is collected for a
research repository. 139 Written informed consent should be obtained in
accordance with the Common Rule, 140 and should clearly describe, as
specifically as possible, the types of research to be conducted, operation of
the repository, the conditions under which samples will be released to
investigators, and procedures for protecting the subject's privacy and
maintaining confidentiality. 141
Asking a parent to consent to the use of her child's bloodspot for
future research is ethically problematic, given that an approved research
protocol does not yet exist. Studies may emerge in the future that cannot be
anticipated at present. Thus, the parental consent would not include specific
research details. Parents can, however, be asked to consent to a particular
class of future research if its potential risks and benefits are explained.142
Bioethicists Bernice Elger and Arthur Caplan describe what they dub the
"European solution," for obtaining consent from subjects for the future
research use of their biological materials. They identify three characteristics
of informed consent for European biobanks: (1) a general consent to future
research use, (2) subsequent approval of the specific research by an ethics
committee, and (3) the subject's right to withdraw his or her biological
138. OFF. FOR HUMAN RESEARCH PROTECTION, Issues to Consider in the Research Use of
Stored Data or Tissues (Nov. 7, 1997), http://www.hhs.gov/ohrp/policy/reposit.html (emphasis
added).
139. 45 C.F.R. § 46.116 (2009).
140. See 45 C.F.R. § 46.116 (setting forth the general requirements for informed consent).
Consent must be obtained only under circumstances that allow a prospective subject sufficient
opportunity to consider whether or not to participate in the research. Id. The elements of informed
consent include the following: the subject must be told that the study involves research and what
is the purpose of the research; the subject must be told of reasonably foreseeable risks or
discomforts, as well as any benefit to the subject or others; and the informed consent form must
include a statement that participation is voluntary, and that the subject may decide at any time not
to continue participation in the research. Id. Subjects also should be given additional information
if it would "meaningfully add to the protection of the rights and welfare of subjects." 45 C.F.R. §
46.109(b).
141. OFF. FOR HUMAN RESEARCH PROTECTION, supra note 138.
142. NAT'L BIOETHICS ADVISORY COMM'N, RESEARCH INVOLVING HUMAN BIOLOGICAL
MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE 49 (1999).
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sample from the research at any time. 143 This general consent, also called
blanket consent, would be particularly suitable in the newborn screening
context. One such model is the Michigan BioTrust for Health. Effective
October 1, 2010, hospitals and midwives will give parents of newborns the
option of signing a consent form if they want their baby's bloodspot sample
to be available for medical research. 144 Before signing the consent form,
the parent is provided with a booklet containing detailed information about
the BioTrust program. 145 The consent form explains that participation in
research is voluntary, that a parent may change her mind at any time, that
when the child is 18, he or she may ask to have his or her bloodspot
removed, and that there is no penalty for choosing not to consent to
research on the bloodspot.146
Taking blanket consent one step further, however, parents could be
allowed to express their preferences for future research, and to limit that
research in ways that are important to them. 147 For example, a parent may
consent to all future research except that relating to cloning, or perhaps
mental health. 148 A general consent could also include consent to specimen
collection, specimen storage, and subsequent specimen transfer to
investigators or other facilities. 149
Newborn bloodspots will become increasingly essential for genetic
research, and in most cases be disseminated post-collection to outside
researchers without additional parental consent if the bloodspots are de-
identified. Thus, it is essential that parents be fully informed about the
general nature of future research-that scientists will use their baby's DNA
to conduct genetic studies, as opposed to general medical research. 150
143. Elger & Caplan, supra note 133, at 663; see also Ellen Wright Clayton, Informed Consent
and Biobanks, 33 J. L. MED. & ETHICS 15, 19-20 (2005).
144. MICH. DEPT. OF COMMUNITY HEALTH, Michigan BioTrust for Health-Consent Options,
http://www.michigan.gov/mdchl0,1607,7-132-2942_4911_4916-244016-,00.html (last visited
May 25, 2011).
145. See MICH. BioTRUST FOR HEALTH, After Newborn Screening: Facts About Using Your
Child's Bloodspots for Research (2010), available at
http://www.michigan.gov/documents/mdch/BiotrustBook 327197_7.pdf (explaining that blood
spots will be stored and used for medical and public health research by way of parental
permission).
146. MICH. DEPT. OF COMMUNITY HEALTH, Michigan BioTrust Consent Form, available at
http://www.phla.info/Michigan%20ConsentFormProofl.pdf (Dec. 2008).
147. See NAT'L BIOETHICS ADVISORY COMM'N, supra note 142, at 49 (stating that "[a]llowing
individuals to express their preferences for future research is consistentwith respecting persons").
148. Drabiak-Syed, supra note 123, at 327.
149. Id. at 326-327.
150. See TEX. HEALTH & SAFETY CODE ANN. § 33.017(c)(4) (West 2009) (providing that de-
identified information "may be released without consent if the disclosure is for: ... (4) research
purposes, provided that the disclosure is approved by an institutional review board or privacy
board of the department").
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Parents ought also to be informed that, while many steps are taken to
protect their child's privacy, and to ensure the security of their child's
genetic information, complete privacy cannot be guaranteed.1"'
The mother's physician is the logical person to discuss with her the
disposition of the newborn's post-screening bloodspots. Obtaining
informed consent in the clinical setting, however, can be stressful,
especially when the decisions to be made do not involve the mother or
baby's clinical care.1 52 The consent process should take place at a time
when the mother-to-be and her physician can comfortably communicate-
certainly not when the birth is imminent. In these circumstances, the
National Bioethics Advisory Commission has recommended that informed
consent to the research use of biological materials should be obtained
separately from informed consent to clinical procedures. 153
V. SECURING THE PUBLIC'S TRUST: THE FALLACY OF PRESUMED CONSENT
States risk loss of the public trust in their well-established NBS
programs if they do not obtain the written, informed consent of parents
before taking bloodspots for the dual purposes of screening and research.
Where research occurs without parental consent, or even within a presumed
consent system, parental confusion and misunderstanding could lead to a
general distrust of essential state NBS programs-an undesirable and
potentially disastrous result. The 2010 SACHDNC Draft National Guidance
recognizes the importance of securing the public trust, and urges that "some
indication of the parents' awareness and willingness to participate should
exist. .. ."154 The 2010 SACHDNC Draft National Guidance leaves the
individual states to deal with the particular form of informed consent. This
section argues that a presumed consent system is not appropriate for
newborn screening research, and that nothing short of the parent's written
and fully informed consent will secure the public trust.
Media headlines reflect public dismay upon discovery that states had
been storing newborn bloodspots for genetic research: "The Government
Has Your Baby's DNA;"155 Texas is Selling Your Baby's Blood;"' 56
151. See Leslie E. Wolf, Advancing Research on Stored Biological Materials: Reconciling
Law, Ethics, and Practice, 11 MINN. J.L. Scl. & TECH. 99, 133 (2010) (discussing recent scientific
developments that question whether DNA can be de-identified).
152. NAT'L BIOETHICs ADVISORY COMM'N, supra note 142, at 63-64 (stating that "stress
level may be high in clinical settings, rendering them not conducive to a consent process that
involves making complex choices regarding issues that are not related directly to clinical care and
that involve speculation about the distant future").
153. Id. at 64.
154. HEALTH RES. AND SERVS. ADMIN., supra note 104, at 19-20.
155. Elizabeth Cohen, The Government has Your Baby's DNA, CNN, Feb. 3, 2010,
http://www.cnn.com/20I0/HEALTH/02/04/baby.dna.govemment/index.hmtl?hpt-C2
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"Parents Outraged at Warehousing of DNA Saved From Newborn Baby
Screening Programs and Used for Clinical Laboratory Testing;"' 57 Suit
Possible Over Baby DNA Sent To Military Lab For National Database;"' 58
"State Agency Swaps Babies' Blood For Supplies;"l 59 "Baby's Blood
Samples Used to Create DNA Database;"' 60 "Newborn Blood Used to
Build Secret Database;"'61 and so forth.
Most states have not yet incorporated into their NBS Programs any
process for informing parents of procedures regarding the storage and
genetic research use of their child's bloodspot. In response to the 2010
SACHDNC Draft National Guidance, some states may now be considering
instituting a presumed consent system. Texas adopted a presumed consent
system in 2009 in response to the litigation addressed herein, 162 and a
similar system is in place in Minnesota. 163 But presumed consent systems
are inadequate for genetic research because they are based on faulty
premise.
Presumed consent in the newborn screening context is based on the
principle that essentially all parents would want to contribute to genetic
research and, if asked, would choose to do so. As the argument goes, a
presumed consent system that makes research participation the default
choice merely makes it easier for parents to do what they already wish to
do. This presumption, however, is inaccurate in several respects. General
support for genetic research does not necessarily equate to a willingness to
donate the blood of one's child to that purpose. Robert Weir and Robert
Olick, in their book "The Stored Tissue Issue," write that a significant
156. Paul Knight, Texas is Selling Your Baby's Blood Without Consent, Lawsuit Says,
HOUSTON PRESS, Dec. 10, 2010,
http://blogs.houstonpress.com/hairballs/2010/12/babys blood lawsuit.php.
157. K. Branz, Parents Outraged at Warehousing of DNA Saved From Newborn Baby
Screening Programs and Used for Clinical Laboratory Testing, DARK DAILY, Mar. 5, 2010,
http://www.darkdaily.com/parents-outraged-at-warehousing-of-dna-saved-from-newborn-
baby-screening-programs-and-used-for-clinical-laboratory-testing.
158. Mary Ann Roser, Suit Possible Over Baby DNA Sent to Military Lab for National
Database, STATEMAN.COM, Feb. 22, 2010, http://www.statesman.com/news/texass-politics/suit-
possible-over-baby-sent-to-military-268714.html.
159. Mary Ann Roser, State Agency Swaps Babies' Blood for Supplies: Companies Use Blood
to Produce and Test Equipment, , STATEMAN.COM, May 10, 2010,
http://www.statesman.com/news/texas-politics/state-agency-swaps-babies-blood-for-supplies-
678302.html.
160. Olivia Conroy, Babies' Blood Samples Used to Create DNA Database, TOP NEWS, May
24, 2010, http:/Itopnews.us/content/220465-babies-blood-samples-used-create-dna-database.
161. Ewen Callaway, Newborns'Blood Used to Build Secret DNA Database, NEW SCIENTIST,
Feb. 24, 2010, http://www.newscientist.com/blogs/shortsharpscience/2010/02/ewen-callaway-
reportertexas-he.html
162. TEX. HEALTH & SAFETY CODE ANN. § 33.0111 (West 2009).
163. MINN. STAT. ANN. § 144.125 Subd. 3 (2011).
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number of Americans are not comfortable with the use of their personal
blood and tissues for scientific studies, even though they generally support
biomedical research. 164 In support of their conclusion, these authors
chronicle several studies surveying public opinion on this issue. 165 In a
University of Iowa Pilot Study of 93 patients, 73% stated they would be
"very" or "somewhat bothered" if their post-diagnostic tissues were used
for research without first obtaining their consent. 166 In another study, 10 to
15 participants in each of sixteen focus groups were asked to review a
simple Model Consent Form for Biological Tissue Banking, which might be
given to a patient prior to surgery. 167 After reviewing the form, participants
expressed suspicions and concerns on several fronts, including privacy
concerns, the type of research that would be done, the possible profit
motives of the researchers, and their "overwhelming" belief that patients
should be given the form several days before the surgery to allow time for
reflection or to change their mind. 168 And in the largest public opinion
study, the Center for Disease Control (CDC) researchers analyzed data from
2,621 participants regarding blood donation and storage for genetics
research. 169 The data showed that 10% of the participants would donate
blood but would not want it stored for long-term research, 27% were not
willing to donate blood for research even if their privacy could be assured,
and 21% would not, under any circumstances, donate blood, or have it
stored for research. 170
Some groups may find genetic research to be objectionable for
religious or cultural reasons. Geneticist and Hopi Indian Frank Dukepoo has
expressed Native American concerns with genetic research relating to
164. ROBERT F. WEIR & ROBERT S. OLICK, THE STORED TISSUE ISSUE 26 (2004) ("tTlhere is
a growing body of evidence suggesting that a significant portion of the American public is not
convinced they want their tissues to be used for scientific studies. Persons surveyed usually
support biomedical research and value the achievements gained through research, but many
remain unconvinced that research studies on banked tissue samples is a trustworthy enterprise that
they should personally support with samples of their own blood, cheek cells, urine, skin, and other
tissues.").
165. See id. at 27-31 (summarizing a University of Iowa Pilot study, a National Action Plan on
breast cancer study, a 1998-1999 National Bioethics Advisory Committee study, and a 2001
Georgetown University/University of Maryland study).
166. Id. at 27.
167. Id.
168. Id at 27-28.
169. Id. at 30. The CDC study, published in 2001, was based on data collected from the 1998
American Healthstyles annual market research survey. Id. The 1998 version of the survey solicited
participant responses to several genetics statements from which the percentage statistics are
drawn. Id.
170. Id. at 30-31 (noting that CDC investigators were concerned with the study results because
they knew that the future of genetic research "depends on public attitudes toward the donation and
long-term storage of blood samples").
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cloning, gene patenting, "immortalized" cell lines, and
commercialization. 171 Some may not want to have their biological materials
used in contraceptive research, mental health studies, or studies of ethnicity
and criminal behavior or violence. Information about an infant's genetic
variation may be of substantial interest to researchers, health insurers, and
marketers, and some persons may be concerned that their samples will be
sold to for-profit commercial enterprises. 172 Still others may be concerned
that the indefinite storage of their blood and identifiable medical
information, if published, may lead to discrimination in health insurance
and employment, or create stigmatization.173 Twila Brase, public health
nurse and President of the advocacy group, Citizen's Council for Health
Freedom, has expressed concern that newborn bloodspot research could
result in a genetic profile that would be used for eugenic purposes.174
In a recent and particularly relevant study, researchers assessed the
attitudes of 1508 parents regarding storage and use of newborn bloodspots
for genetic research. 175 Not surprisingly, 55.7% of the 1508 parents
surveyed were "very unwilling" to permit research on their child's
bloodspot without their permission.176 Only 11.3% were "very willing" to
permit use of the NBS sample without their permission.177 Even when
parental permission was sought, 23.8% remained either "very unwilling," or
"somewhat unwilling" to permit research use of the samples.178 Another
study examined women's willingness to enroll their children in a
hypothetical pediatric biobank. 179  The research revealed significant
misconceptions about what participation in a biobank would mean, and
171. Sensitivities and Concerns of Research in Native American Communities: Hearing Before
the Nat'l Bioethics Advisory Comm'n, 105th Cong. 25-27 (1998) (statement of Frank Dukepoo),
available at http://govinfo.library.unt.edu/nbac/transcripts/jul98/dayl.pdf.
172. See NAT'L BIOETHICS ADVISORY COMM'N, supra note 142, at 49 (generally describing
"objectionable, unacceptable, or questionable research"); see also Kenneth D. Mandl et al., supra
note 128, at 269 (introducing reports from a study defining "current practice among newborn
screening programs").
173. NAT'L BIOETHICS ADVISORY COMM'N, supra note 142, at 44-45.
174. Twila Brase, Newborn Genetic Screening, the New Eugenics? The Case for Informed
Consent Requirements for Genetic Testing, Baby DNA Storage and Genetic Research, CCHC
REPORT, Apr. 2009, at 10.
175. Beth A. Tarini, et al., Not Without My Permission: Parents' Willingness to Permit Use of
Newborn Screening Samples for Research, 13 PUB. HEALTH GENOMICS 1, 2-32, (2009), available
at http://www.cchfreedom.org/pdf/tarini biobanking%20paper-parent%20attitudes.pdf.
176. Id. at 3-4.
177. Id. at 3.
178. Id.
179. See Alon B. Neidich, et al., Empirical Data About Women's Attitudes Towards a
Hypothetical Pediatric Biobank, 146 AM. J. MED. GENETICS 297, 298 (2008), available at
http://www3.interscience.wiley.com/journal/117888916/abstract?CRETRY=I&SRETRY=0
(surveying women eighteen years of age or older and within seventy-two hours of child delivery
at the University of Chicago Hospitals).
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misunderstanding about who would have access to the information and how
information would be protected. 80 26% of the 207 women polled did not
feel that they had enough information to decide whether or not to enroll
their child.181
Public officials should not attempt to bypass parental consent in an
effort to avoid their refusal to participate in genetic research. Bypassing
parental consent serves only to fuel the flames of government mistrust,
reinforce common misconceptions, and confirm society's deepest fears
about genetic research. Presumed consent is the ideological opposite of
written informed consent. In his article Presumed Consent to Organ
Donation: Its Rise and Fall in the United States, David Orentlicher reviews
America's failed forty-year-long limited experiment with presumed
consent statutes designed to increase the supply of scarce organs, and
concludes that presumed consent advocates "a policy that goes against the
grain of American individualism and is more at home in countries with a
stronger communitarian ethic."1 82
Parents deserve straightforward information about what will happen to
their child's DNA sample, how their child's privacy will be protected, and,
to the extent known, the type of research in which the sample will be used,
and the conditions under which samples will be shared. Providing parents
with clearly communicated written information about the state's newborn
bloodspot storage and research program, and obtaining their voluntary
written consent is beneficial in two important respects. First, obtaining
written informed consent from parents exhibits a respect for parental
autonomy in making decisions involving their child's body. It
acknowledges the child whose information and blood are provided for
research, and recognizes the parent's contribution to the advancement of
medical science.18 3 Second, engaging in the process of informed consent is
an important part of gaining and maintaining the public trust in genetic
research. Ultimately, science and society will benefit. As researchers in the
hypothetical pediatric biobank study noted, "understanding correlated with
enrollment."1 84
When parents are fully informed, and their choice is respected, they
are more likely to trust the program, and want to participate. But merely to
180. See id at 300(noting confusion about the privacy of the information and whether or not
family members, law enforcement and researchers at other institutions could gain access to the
information).
181. Id. at 299.
182. David Orentlicher, Presumed Consent to Organ Donation: Its Rise and Fall in the United
States, 61 RUTGERS L. REv. 295, 296-297 (2009) (noting that presumed consent laws are more
common in Austria, Belgium, France, Italy, and Sweden).
183. Ellen Wright Clayton, supra note 143, at 19.
184. Neidich et al., supra note 179, at 302.
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presume that parents would consent to genetic research using their child's
blood is ... well, presumptuous . . . and inaccurate. 18 5 Equally misguided is
the presumption that every parent who is opposed to storing their child's
bloodspot for research will understand that they must take the initiative, and
act affirmatively to exclude their child from future research. A presumed
consent system for genetic research risks loss of public trust, and may
ultimately undermine the essential newborn screening program. 186 The
time is right for States to adopt the federal regulations for the protection of
human subjects, and to require IRB review and approval of newborn
bloodspot collection, storage, and dissemination procedures. A transparent
approach, based on parental written informed consent, will go far in
assuring the public's trust in essential state newborn screening programs.
185. See id. at 299 (indicating at least twenty percent of women would not consent to enrolling
their child into a hypothetical biobank, thus hypothetically not consenting to the genetic research
of their child's blood).
186. See Clayton, supra note 133, at 802 ("Uliimately, the silent creation of biobanks from
clinical information and specimens turns out simply to be a bad idea, no matter what the law
says.").
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